The use of cardioplegia (pharmacologically induced electromechanical arrest) to achieve the ideal conditions for cardiac surgical operations was introduced over 20 years ago in clinical practice. Since then a number of ingredients have been added in various proportions to different cardioplegic solutions and their evaluation in experimental laboratories and clinical practice has continued. Any additive to a cardioplegic solution should be investigated in experimental laboratories and asanguinous cardioplegie solutions should be carefully formulated to avoid extremes of ionic concentrations, pH and osmolality. Cold blood cardioplegia has not been found advantageous when compared with conventional asanguinous solutions. A combination of pharmacologically induced arrest with cold asanguinous cardioplegie solution and topical hypothermia protects the myocardium better than topical hypothermia alone or normothermic cardioplegia, and continuous infusion of cardioplegie solutions has proved no better than multidose administration. Multidose administration of cold cardioplegie solutions with moderate hypothermia and surface cooling has been found most satisfactory for prolonged aortic cross clamping (up to, two hours). Use of cardioplegia in recent years has undoubtedly improved the prognosis of a number of patients undergoing surgical correction of complex cardiac lesions. © 1980 Canadian Anesthesiologists.
CITATION STYLE
Chatrath, R. R., Kaul, T. K., & Walker, D. R. (1980). Myocardial protection during cardioplegia in open-heart surgery: a review. Canadian Anaesthetists’ Society Journal, 27(4), 381–388. https://doi.org/10.1007/BF03007460
Mendeley helps you to discover research relevant for your work.